JPWO2021200259A1 - - Google Patents

Info

Publication number
JPWO2021200259A1
JPWO2021200259A1 JP2022511913A JP2022511913A JPWO2021200259A1 JP WO2021200259 A1 JPWO2021200259 A1 JP WO2021200259A1 JP 2022511913 A JP2022511913 A JP 2022511913A JP 2022511913 A JP2022511913 A JP 2022511913A JP WO2021200259 A1 JPWO2021200259 A1 JP WO2021200259A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022511913A
Other languages
Japanese (ja)
Other versions
JP7698318B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021200259A1 publication Critical patent/JPWO2021200259A1/ja
Priority to JP2025095125A priority Critical patent/JP2025120320A/ja
Application granted granted Critical
Publication of JP7698318B2 publication Critical patent/JP7698318B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022511913A 2020-03-30 2021-03-19 Ｖｉｐｒ２アンタゴニストペプチド Active JP7698318B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025095125A JP2025120320A (ja) 2020-03-30 2025-06-06 Ｖｉｐｒ２アンタゴニストペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020059721 2020-03-30
JP2020059721 2020-03-30
PCT/JP2021/011316 WO2021200259A1 (ja) 2020-03-30 2021-03-19 Ｖｉｐｒ２アンタゴニストペプチド

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025095125A Division JP2025120320A (ja) 2020-03-30 2025-06-06 Ｖｉｐｒ２アンタゴニストペプチド

Publications (2)

Publication Number Publication Date
JPWO2021200259A1 true JPWO2021200259A1 (https=) 2021-10-07
JP7698318B2 JP7698318B2 (ja) 2025-06-25

Family

ID=77928204

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022511913A Active JP7698318B2 (ja) 2020-03-30 2021-03-19 Ｖｉｐｒ２アンタゴニストペプチド
JP2025095125A Pending JP2025120320A (ja) 2020-03-30 2025-06-06 Ｖｉｐｒ２アンタゴニストペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025095125A Pending JP2025120320A (ja) 2020-03-30 2025-06-06 Ｖｉｐｒ２アンタゴニストペプチド

Country Status (5)

Country Link
US (1) US20230174582A1 (https=)
EP (1) EP4137502A4 (https=)
JP (2) JP7698318B2 (https=)
CN (1) CN115298194A (https=)
WO (1) WO2021200259A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118742316A (zh) 2022-02-25 2024-10-01 一丸自然美健有限公司 用于抑制癌转移的vipr2拮抗肽
JP7417010B1 (ja) * 2022-03-31 2024-01-17 国立大学法人 香川大学 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504802A (ja) * 1994-06-08 1998-05-12 ペプター リミテッド コンホメーション的に固定された主鎖環化ペプチド類似体
JP2004512530A (ja) * 2000-10-23 2004-04-22 ザ　プロクター　アンド　ギャンブル　カンパニー 血管活性腸管ペプチド受容体を用いて筋量または筋機能を調節する化合物を同定するための方法
JP2008510679A (ja) * 2004-06-16 2008-04-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
JP2009519212A (ja) * 2005-10-26 2009-05-14 イーライ リリー アンド カンパニー 選択的ｖｐａｃ２受容体ペプチドアゴニスト

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5280683B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
TW201811817A (zh) * 2016-09-13 2018-04-01 日商第一三共股份有限公司 血小板反應素１結合肽
CN108218971B (zh) * 2016-12-21 2021-01-22 海南大学 α-芋螺毒素肽TxID新突变体、其药物组合物及用途
JP7417010B1 (ja) * 2022-03-31 2024-01-17 国立大学法人 香川大学 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504802A (ja) * 1994-06-08 1998-05-12 ペプター リミテッド コンホメーション的に固定された主鎖環化ペプチド類似体
JP2004512530A (ja) * 2000-10-23 2004-04-22 ザ　プロクター　アンド　ギャンブル　カンパニー 血管活性腸管ペプチド受容体を用いて筋量または筋機能を調節する化合物を同定するための方法
JP2008510679A (ja) * 2004-06-16 2008-04-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
JP2009519212A (ja) * 2005-10-26 2009-05-14 イーライ リリー アンド カンパニー 選択的ｖｐａｃ２受容体ペプチドアゴニスト

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 503, JPN6021020440, 1 August 2018 (2018-08-01), pages 1973 - 1979, ISSN: 0005485695 *
BIOPOLYMERS (PEPTIDE SCIENCE), vol. 106, no. 6, JPN6021020443, 14 May 2016 (2016-05-14), pages 843 - 852, ISSN: 0005485696 *
CHEM. SOC. REV., vol. 44, JPN7021001942, 8 September 2014 (2014-09-08), pages 91 - 102, ISSN: 0005485697 *
NATURE CHEMISTRY, vol. 6, JPN7021001943, 31 August 2014 (2014-08-31), pages 1009 - 1016, ISSN: 0005485698 *

Also Published As

Publication number Publication date
JP7698318B2 (ja) 2025-06-25
EP4137502A4 (en) 2024-02-28
US20230174582A1 (en) 2023-06-08
CN115298194A (zh) 2022-11-04
EP4137502A1 (en) 2023-02-22
WO2021200259A1 (ja) 2021-10-07
JP2025120320A (ja) 2025-08-15

Similar Documents

Publication Publication Date Title
JPWO2021200259A1 (https=)
JP1711864S (https=)
CN305725051S (https=)
CN305634336S (https=)
CN305742973S (https=)
CN305742608S (https=)
CN305741615S (https=)
CN305563431S (https=)
CN305723673S (https=)
CN305554243S (https=)
CN305722151S (https=)
CN305720953S (https=)
CN305719053S (https=)
CN305717749S (https=)
CN305534878S (https=)
CN305533737S (https=)
CN305533736S (https=)
CN305716231S (https=)
CN305532732S (https=)
CN305532469S (https=)
CN305532187S (https=)
CN305531165S (https=)
CN305530700S (https=)
CN305530394S (https=)
CN305712760S (https=)

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231120

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250606

R150 Certificate of patent or registration of utility model

Ref document number: 7698318

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150